Dapaglyn Dapagliflozin News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Dapaglyn dapagliflozin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Dapaglyn Dapagliflozin Today - Breaking & Trending Today

Cadila Healthcare Ltd Q3FY21 consolidated net profit higher at Rs. 527.2. crore

Cadila Healthcare Ltd Q3FY21 consolidated net profit higher at Rs. 527.2. crore
Posted On:
CADILA HEALTHCARE LTD. has reported financial results for the period ended December 31, 2020.
Financial Results (Q3 FY20-21) - QoQ Comparison
The company has reported total income of Rs.3823.1 crores during the period ended December 31, 2020 as compared to Rs.3847.5 crores during the period ended September 30, 2020.
The company has posted net profit / (loss) of Rs.527.2 crores for the period ended December 31, 2020 as against net profit / (loss) of Rs.473.4 crores for the period ended September 30, 2020.
The company has reported EPS of Rs.5.15 for the period ended December 31, 2020 as compared to Rs.4.62 for the period ended September 30, 2020. ....

United States , Dapaglyn Dapagliflozin , Zydus Cadila , American Association , Cadila Healthcare Ltd , Time Zone , Profit After Tax , Chronic Obstructive Pulmonary Disorder , Long Acting Muscarinic Antagonist , Non Alcoholic Fatty Liver Disease , Non Alcoholic Steatohepatitis , Liver Diseases , Primary Biliary Cholangitis , Fast Track Designation , Orphan Drug Designation , Pegylated Interferon , ஒன்றுபட்டது மாநிலங்களில் , ஜய்துச் காடிலா , அமெரிக்கன் சங்கம் , காடிலா சுகாதாரம் லிமிடெட் , நேரம் ஸோந் , நாள்பட்ட தடைசெய்யும் நுரையீரல் கோளாறு , அல்லாத ஆல்கஹால் கொழுப்பு கல்லீரல் நோய் , கல்லீரல் நோய்கள் , வேகமாக டிராக் பதவி , ஆர்ஃபந் மருந்து பதவி ,

Cadila Healthcare Q3 results: Net profit up 41% to Rs 527 crore

Cadila Healthcare Q3 results: Net profit up 41% to Rs 527 crore
SECTIONS
Last Updated: Feb 05, 2021, 04:02 PM IST
Share
Synopsis
The company had posted a net profit of Rs 373.9 crore for the corresponding period of the previous fiscal, Cadila Healthcare said in a filing to BSE.
Consolidated revenue of the company stood at Rs 3,795.6 crore for the quarter under consideration. It was Rs 3,638.1 crore for the same period a year ago, it added.
Related
NSE
Drug firm
Cadila Healthcare on Friday reported a 41 per cent rise in its consolidated net profit to Rs 527.2 crore for the quarter ended December 2020 on account of robust sales in all segments. ....

United States , Dapaglyn Dapagliflozin , Apurvas Diwanji , Zydus Group , Drug Administration , Cadila Healthcare , United States Food , Pegylated Interferon , Chronic Obstructive Pulmonary Disorder , Independent Director , India Geography , United States Food And Drug Administration , ஒன்றுபட்டது மாநிலங்களில் , அபுர்வஸ் திவான்ஜி , ஜய்துச் குழு , காடிலா சுகாதாரம் , ஒன்றுபட்டது மாநிலங்களில் உணவு , நாள்பட்ட தடைசெய்யும் நுரையீரல் கோளாறு , சுயாதீனமான இயக்குனர் , இந்தியா நிலவியல் ,

Zydus Cadila s net profit up 41 in Q3 to Rs 527 crore-ANI

Zydus Cadila s net profit up 41 in Q3 to Rs 527 crore-ANI
businessworld.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businessworld.in Daily Mail and Mail on Sunday newspapers.

Dapaglyn Dapagliflozin , Zydus Cadila , Drug Administration , ஜய்துச் காடிலா ,

Cadila Healthcare Q3 Net Profit Up 41% To Rs 527 Crore

Cadila Healthcare Q3 Net Profit Up 41% To Rs 527 Crore
moneycontrol.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from moneycontrol.com Daily Mail and Mail on Sunday newspapers.

United States , Dapaglyn Dapagliflozin , Apurvas Diwanji , Zydus Group , Drug Administration , Cadila Healthcare , United States Food , Pegylated Interferon , Chronic Obstructive Pulmonary Disorder , Independent Director , Cadila Healthcare Q3 Earnings , Cadila Healthcare Net Profit Loss , Cadila Healthcare Revenue , ஒன்றுபட்டது மாநிலங்களில் , அபுர்வஸ் திவான்ஜி , ஜய்துச் குழு , காடிலா சுகாதாரம் , ஒன்றுபட்டது மாநிலங்களில் உணவு , நாள்பட்ட தடைசெய்யும் நுரையீரல் கோளாறு , சுயாதீனமான இயக்குனர் , காடிலா சுகாதாரம் நிகர ப்ராஃபிட் இழப்பு , காடிலா சுகாதாரம் வருவாய் ,

Zydus Cadila's net profit up 41 pc in Q3 to Rs 527 crore

Zydus Cadila s net profit up 41 pc in Q3 to Rs 527 crore
ANI |
Updated: Feb 05, 2021 17:07 IST
Ahmedabad (Gujarat) [India], February 5 (ANI): Pharmaceutical major Zydus Cadila said on Friday its profit after tax was up by 41 per cent to Rs 527 crore in Q3 FY21 as compared to the corresponding quarter of previous year.
Consolidated revenues moved up by 4 per cent to Rs 3,796 crore consolidated net sales by 6 per cent to Rs 3,754 crore. Earnings before interest, depreciation and tax (EBIDTA) were up by 16 per cent to Rs 807 crore.
The company s business in India, which comprises human health formulations business, consumer wellness business and animal health business posted 20 per cent growth in the quarter ended December 2020 with revenues of Rs 1,643 crore. ....

Dapaglyn Dapagliflozin , Zydus Cadila , Drug Administration , Profit After Tax , Net Sales , Human Health Formulations Business , Consumer Wellness Business , Animal Health Business , Us Formulations Business , ஜய்துச் காடிலா , நிகர விற்பனை , மனிதன் ஆரோக்கியம் சூத்திரங்கள் வணிக , நுகர்வோர் ஆரோக்கியம் வணிக , விலங்கு ஆரோக்கியம் வணிக , எங்களுக்கு சூத்திரங்கள் வணிக ,